Second Webinar in the ISPOR-IVI Series Explores Whether Value Assessments are Up to the Task in the Age of COVID-19

The second part of a five-part webinar series examining value assessment in the COVID-19 era hosted by ISPOR and the Innovation and Value Initiative (IVI) will explore whether the methods on which health economists have relied are up to task or in need of improvement for the pandemic era. Moderated by Lou Garrison, PhD (University [...]

2020-09-09T09:43:29-04:00August 24th, 2020|News|

Exploring Patient Heterogeneity and Diversity in Treatment Responses

Author: Jennifer Bright, MPA Everyone hopes for a COVID vaccine so our lives can return to normal. Yet, we know that even if clinical trials prove a vaccine's effectiveness, our society will still have to endure a long process of distribution. I'm personally willing to wait for a vaccine for healthcare workers, the elderly, and [...]

2020-12-29T17:01:22-05:00August 20th, 2020|Blog|

Value Assessment During the COVID-19 Pandemic

The COVID-19 pandemic is raising new questions about how we approach value assessment. As always, IVI urges experts to use transparency, real world data, and seek consensus. Sam Nussbaum, President of the IVI Board of Directors, shares his thoughts in a commentary in STAT. Read the full commentary here.

2020-06-30T09:53:00-04:00June 18th, 2020|News|

Measuring Value: COVID-19 Forces a Reassessment

Authors: Patricia Deverka, Jennifer Bright, Louis Garrison, Samuel Nussbaum We have seen the COVID-19 pandemic decimate people’s lives, health care systems, and the global and US economy, with investments by the US government exceeding $4 trillion dollars and with unemployment approaching 20%. In recent days, numerous articles have speculated on the pricing for Gilead’s new [...]

2020-12-29T17:02:53-05:00May 20th, 2020|Blog|
Go to Top